Radiotherapy (RT) is a major modality for cancer treatment, but its efficacy is often compromised by the resistance caused by tumor-specific microenvironment including acidosis and hypoxia. For an effective RT, concurrent administration of radiosensitizer with RT has been emphasized. However, most anticancer agents enhancing radiotherapeutic efficacy have obstacles such as poor solubility and severe toxicity. Paclitaxel (PTX), a well-known radiosensitizer, is insoluble in water and needs toxic solvent like Cremophor EL. Nanomaterials in drug delivery systems have been utilized for improving the drawbacks of anti-cancer drugs. Solubilization, tumor accumulation, and toxicity attenuation of drug by nanomaterials are suitable for enhancement of radiotherapeutic efficacy. In this study, PTX was incorporated into pH-sensitive block copolymer micelle (psm-PTX), polyethylene glycol-graft-poly(β-amino ester), and preclinically evaluated for its effect on RT. The size of psm-PTX was 125.7 ± 4.4 nm at pH 7.4. psm-PTX released PTX rapidly in the acidic condition (pH 6.5), while it was reasonably stable in the physiologic condition (pH 7.4). The clonogenic assay showed that psm-PTX greatly sensitized human non-small-cell lung cancer A549 cells to radiation. In the xenograft tumor model, the combination of psm-PTX and radiation significantly delayed the tumor growth. These results demonstrated the feasibility of psm-PTX to enhance the chemoradiotherapeutic efficacy.
Introduction
Radiotherapy (RT) is a major treatment for many cancers, especially non-small-cell lung cancer (NSCLC), but the overall cure rate and survival rate remain low because of radioresistance by proficient repair of radiation damage, accelerated cell repopulation, hypoxia, various molecular inhibitors of cell death, and so on [1] . To increase tumor control, concurrent administration of radiosensitizer with RT has been a common treatment regimen [2] . Most radiosensitizers are mainly anticancer agents. One of well known radiosensitizers is paclitaxel (PTX), which is being widely studied for clinical trials [3] . However, PTX needs toxic solvent such as Cremophor EL for clinical application due to its insolubility and has toxicities such as neutropenia, peripheral sensory neuropathy, dermatitis, and hypersensitivity reaction. Thus, there has been passionate interest in developing alternative formulation of PTX. Journal of Nanomaterials Nanomaterials in drug delivery systems (DDSs) have been playing a key role in the medical field, especially anticancer therapy. Nanomaterials such as polymeric nanoparticles and micelles are associated with solubilization of lowsolubility drugs. PTX-loaded NK105 micellar nanoparticles, Abraxane (PTX-loaded albumin particle), Xyota (polymerconjugated PTX), and Tocosol (tocophenol-based PTX), improve the low solubility of PTX. They are being evaluated in preclinical and clinical studies [4, 5] . Furthermore, these nanomaterials are suitable for drug accumulation in tumor by the enhanced permeability and retention (EPR) effect. Recently many efforts have been dedicated to study modified nanomaterials with tumor cell targeting moieties or tumor environmental sensitivity (temperature, pH, and enzyme activity). These properties control cell selectivity, cellular uptake, and drug release. Among them, tumor acidity, slightly a low extracellular pH (∼6.8) [6] , is exploited for DDS. pH-sensitive nanomaterials are suited for controlled drug release by the normal/cancer cells microenvironmental difference. pH-sensitive drug carriers have been developed to include liposome, micelles, dendrimers, and drug-polymer conjugates [7] [8] [9] . In our previous study, methyl ether poly(ethylene glycol)-poly(β-amino ester) polymeric micelles (MPEG-PM) was synthesized and evaluated as a PTX-loaded smart carrier in vitro [10] . Moreover, camptothecin-incorporated MPEG-PM was reported for cancer therapeutic efficacy [11] . Herein, we evaluated PTX-loaded pH-sensitive micelle (psm-PTX) as a radiosensitizer for chemoradiotherapy in NSCLC both in vitro and in vivo.
Materials and Methods

Preparing psm-PTX.
pH-sensitive block copolymer micelle (psm), of which M n is 13,000 g·mol −1 and which contains 4 mol-% PEG, was obtained according to the previous study [12] . PTX was conjugated with psm using anhydrous dichloromethane as reported previously [13] . The size distribution of psm-PTX was measured by dynamic light scattering (DLS) at 25
• C.
PTX Release from psm-PTX In Vitro.
To determine the release of PTX depending on pH, psm-PTX (1 mg/mL) solution at pH 6.0-8.0 was prepared. The pH of psm-PTX was adjusted stepwise with NaOH solution and immediately filtered. To measure the release of PTX depending on time, 1 mg/mL of psm-PTX was loaded to a dialysis membrane (MWCO, 3500) and immersed in 20 mL of the medium at 37
• C. At predetermined time intervals, the medium was withdrawn. The concentration of PTX was measured by HPLC as described in the previous study [12] . Briefly, the mobile phase was changed linearly from acetonitrilewater (50 : 50 v/v) to acetonitrile-water (90 : 10 v/v), and a C-18 reverse-phase column was used. The flow rate was 0.5 mL/min.
Clonogenic Assay.
Human lung adenocarcinoma A549 cells purchased from the American Type Culture Collection (ATCC) were maintained in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Invitrogen) and 1% penicillin/streptomycin under a humidified atmosphere of 5% CO 2 at 37
• C. A549 cells were seeded from 100 to 1,000 cells/well in 6-well plate and treated with PTX or psm-PTX (0.2 nM as PTX). PTX was dissolved by 50% Cremophor EL/ethanol and diluted one-fifth by phosphate-buffered saline (pH 7.4) before use. After 2 h, A549 cells were irradiated at 2 Gy using a 6 MV photon beam linear accelerator (CL/1800, Varian Medical System, Palo Alto, CA). The cells were incubated for 11 days to allow colony formation. The colonies composing of over 50 cells were counted, and the survival fraction was calculated as in the previously study [14] . Plating efficiency was defined from nonirradiated cells as (mean colonies counted)/(cells plated). Survival fraction was calculated as (mean colonies counted)/[(cells plated) × (plating efficiency)].
Tumor Growth Delay.
All experiments were performed following the protocol approved by the Institutional Animal Care and Use Committee of ASAN Institute for Life Science. A549 cells (5 × 10 5 cells) were implanted subcutaneously into the right hind leg of five-week-old male BALB/c nude mice weighing about 20 g (Japan SLC, Shizuoka, Japan), as previously described [15] . When the tumors grew to about 100 mm 3 , the mice were randomized and divided into the experimental groups (n = 5/group). The mice were intravenously injected with 10 mg/kg of psm-PTX (as at a concentration of PTX) or equal amount of psm (300 mg/kg) without PTX as a control. After 2 h, tumors were irradiated to 5 Gy. The tumor volume was calculated by the following formula: V = (longest dimension) × (shortest dimension) 2 × 0.5.
Results and Discussions
Characterization of psm-PTX.
For pH-sensitivity and hydrophilic block, psm consisted of poly(β-amino ester) and PEG (Figure 1(a) ). Molecular weight of PEG was 2,000, which was known to be degradable without toxicity [16, 17] . Furthermore, the micellization/demicellization transition of psm was reported at the sharp pH transition between 6.4 and 6.8 in previous work [11] . PTX was easily loaded into psm without an organic solvent. Loading efficiency of PTX was 48%, and loading amount was 2.3% (w/w). Lyophilized psm-PTX was reconstructed by sterilized water for the evaluation of psm-PTX. As a result, psm-PTX improved the water solubility of PTX by hydrophilic block, suggesting it excluded cremophor EL-induced toxicity. The size of psm-PTX was determined as 125.7 ± 4.4 nm at pH 7.4 by DLS, while psm was 27.7 ± 1.2 nm (Figure 1(b) ). The encapsulation of PTX in psm expanded the size of polymeric micelles. These results suggested that the properties of psm-PTX (its size, solubility, and pH sensitivity) could play a smart carrier role in chemotherapy. a pH-dependent drug release according to the different pH conditions (Figure 2(a) ). Below pH 6.8, PTX was dramatically released over 50% from psm-PTX. Moreover, 50% of PTX in psm-PTX was rapidly released PTX within 30 min and then psm-PTX remained less 10% PTX at 4 h under the pH 6.5 condition, indicating that psm-PTX was demicellized at the acidic pH (Figure 2(b) ). The results suggested that psm-PTX could trigger the PTX release at tumor site due to the acidic environment of the tumor site. On the other hand, psm-PTX was stable and slowly released for 12 h at 37
pH-Dependent Drug Release of psm-PTX. psm-PTX was investigated for controlled drug release. psm-PTX showed
• C in pH 7.4 (Figure 2(b) ), suggesting that psm-PTX preserved PTX during systemic circulation. However, residual PTX did not remain for a day at normal pH, and thus the modified formulation of psm-PTX is being studied for a long circulation.
Radiosensitizing Effect of psm-PTX in A549 Human Lung
Cancer Cells. The radiosensitizing effect of psm-PTX was evaluated on A549 cells by clonogenic assay (Figure 3) . Survival fraction of psm did not differ from control at any pH. Survival fraction of PTX was similar to that of ionizing radiation (IR, 2 Gy), and the combination of PTX with IR showed the expectative sensitizing effect. Importantly, psm-PTX showed greatly lower survival fraction than PTX, suggesting that psm-PTX was uptaken rapidly into cells and internalized psm-PTX was demicellized by the endosomal acid pH (below pH 6.5). Especially, the combination of psm-PTX with IR showed more cytotoxicity than psm-PTX or IR in the low acidic pH environment (pH 6.5). These results showed that psm-PTX had a potential to exert an enhanced radiosensitization effect at the acidic pH condition.
In Vivo Tumor Growth Delay of the Combination of psm-PTX with IR.
The acidic environment of the tumor is an important property for active targeting. In the previous study, the tumor growth delay of anticancer drug was enhanced by using camptothecin-(CPT-) loaded pHresponsive polymeric micelles (CPT-pH-PMs) [11] . In this study, the radiotherapeutic efficacy of psm-PTX was evaluated in mice bearing A549-derived tumor. The psm-PTX was administered by intravenous injection via tail vein. As shown in Figure 4 , psm-PTX-treated group showed similar tumor growth to IR-treated group. The combination of psm-PTX with IR significantly enhanced the radiotherapeutic efficacy. At 21 days after administration, psm-PTX, IR, and the combination of psm-PTX with IR suppressed the tumor size by 71%, 75%, and 31%, respectively. During this examination, the change of body weight was not shown in any group. The results indicated that psm-PTX as a radiosensitizer was able to be utilized for chemoradiotherapy. Chemoradiotherapy is a standard treatment regimen for various cancers. In addition, nanomaterials as drug carriers induce the enhancement of therapeutic efficacy as well as the attenuation of toxicity. Abraxane, approved by US Food and Drug Administration, was also reported to improve radiotherapy [18] . Although several pH-responding carriers containing PTX have been reported for chemotherapeutics, an utilization of pH-responding carrier as radiosensitizer has not been reported. Therefore, we aimed to apply psm-PTX, a smart carrier responding the tumor-specific microenvironment such as low pH, to improve radiotherapeutic efficacy. The results of this study demonstrated the feasibility of psm-PTX to enhance the chemoradiotherapeutic efficacy. Inasmuch as this study was designed primarily for the enhancement of concurrent chemoradiotherapy, we have focused on the radiosensitization effect in the presence of psm-PTX during radiation. Although we have not evaluated the effect of psm-PTX on a sequential chemoradiotherapy in which chemotherapy and RT are separately given to tumor, further investigation to confirm the efficacy of psm-PTX on sequential chemoradiotherapy is clearly warranted. This study suggests that psm-PTX as a radiosensitizer would be a potential candidate for clinical chemoradiotherapy trials.
